Literature DB >> 7639424

Nonocclusive ischemic colitis following glycerin enema in a patient with coronary artery disease. A case report.

R Y Chang1, C H Tsai, Y S Chou, T C Wu.   

Abstract

Acute colonic ischemia is the most common form of intestinal ischemia. Nonocclusive ischemic colitis contributes to some of these disorders. Heart disease, such as congestive heart failure, myocardial infarction, arrhythmias, aortic valve disease, and atherosclerotic cardiovascular disease, account for many of its risk factors. The majority of cases are associated with severe congestive heart failure with low cardiac output, or disease states resulting in dehydration, or the splanchnic vasoconstrictive effect of some medications. Reactive splanchnic vasoconstriction is responsible for nonocclusive ischemic colitis. Ischemic colitis induced by a cleansing enema has been reported once before. The authors present a case of coronary artery disease complicated by colonic ischemia following glycerin enema in preparation for coronary bypass surgery. Reactive inferior mesenteric artery spasm in response to the enema was noted in this case, rather than diffuse mesenteric artery spasm in response to low cardiac output state and vasoconstrictive drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639424     DOI: 10.1177/000331979504600816

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

Review 1.  [Concomitant cardiovascular conditions in intestinal illness].

Authors:  P Rellecke; B E Strauer
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

2.  Ischemic enterocolitis examined by colonoscopy and selective angiography.

Authors:  Lei He; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

3.  Ischemic colitis after enema administration: Incidence, timing, and clinical features.

Authors:  Yura Ahn; Gil-Sun Hong; Ju Hee Lee; Choong Wook Lee; Seon-Ok Kim
Journal:  World J Gastroenterol       Date:  2020-11-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.